leisure time -WSS

leisure time

author：explore 2025-09-29 22:51:37 - browse：519

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： New Medicare drug pricing powers could soon be upended in court

Wikipedia

knowledge

WSS

Abbott's new heart device gets FDA advisory panel nod

ACIP vaccine advisory panel sees its vacancies filled

Readout LOUD podcast: live from JPM 2024

Latigo launches with $135 million for Vertex

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Risky weight loss products often used by teens globally, per study

focus

leisure time

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

The SUPPORT Act is critical to fighting the opioid crisis

Medical records are filled with copy

Three issues to watch in global health in 2024

Apple is now the first public company to be valued at $3 trillion

STAT Boddities: What happens to the brain when we get scared?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Too many hospitalized Covid

Cancer drug shortages should be causing more outrage

AMAs digital advisors table RPM coding reform proposal, again

focus

Why don't Americans have at

The SUPPORT Act is critical to fighting the opioid crisis

HHS names first

Juul documents reveal insider tactics on political lobbying

Ebola vaccine can save some who are already sick, per new study

GSK to buy asthma

Wikipedia

knowledge

knowledge

leisure time